Nivel de adherencia al tratamiento antituberculoso en pacientes tratados con dosis independientes comparados con aquellos que reciben dosis fijas combinadas
No Thumbnail Available
Date
2025
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
La tuberculosis continúa siendo una de las principales causas de mortalidad a nivel mundial. Actualmente, los pacientes sensibles que reciben tratamiento antituberculoso pueden ser prescritos con Dosis Independientes (DI) o Dosis Fijas Combinadas (DFC), diferenciándose por el número de tabletas. Evaluar la adherencia al tratamiento es esencial para mejorar su efectividad. Este estudio tuvo como objetivo determinar la adherencia al tratamiento antituberculoso entre pacientes que reciben DI y DFC. Se realizó un estudio Básico – Descriptivo de diseño transversal en la Red de Salud Trujillo con 114 pacientes diagnosticados de tuberculosis, de los cuales el 44.7% reciben DFC y 55.3% DI. Se aplicó un cuestionario validado de 12 preguntas a cada paciente que acudió al centro de salud. Los resultados mostraron una adherencia del 90.2% en el grupo DFC y del 87.3% en el grupo DI, sin diferencias estadísticamente significativas entre ambos grupos (p=0.6434). A pesar de la alta adherencia en ambos esquemas, no se encontró una diferencia significativa. Aunque la evidencia sugiere que las DFC pueden facilitar el cumplimiento terapéutico, se requieren más estudios para investigar la eficacia y la adherencia en diversos contextos.
Tuberculosis remains one of the leading causes of mortality worldwide. Currently, susceptible patients receiving anti-tuberculosis treatment can be prescribed with either Independent Doses (ID) or Combined Fixed Doses (CFD), differentiated by the number of tablets. Assessing adherence to treatment is essential to improve its effectiveness. This study aimed to determine adherence to anti-tuberculosis treatment among patients receiving ID and FDC. A cross-sectional basic-descriptive study was carried out in the Trujillo Health Network with 114 patients diagnosed with tuberculosis, of whom 44.7% receive DFC and 55.3% DI. A validated 12-question questionnaire was applied to each patient attending the health centre. The results showed 90.2% adherence in the DFC group and 87.3% in the DI group, with no statistically significant differences between the two groups (p=0.6434). Despite the high adherence in both schemes, no significant difference was found. Although evidence suggests that CBD may facilitate adherence, further studies are needed to investigate efficacy and adherence in various settings.
Tuberculosis remains one of the leading causes of mortality worldwide. Currently, susceptible patients receiving anti-tuberculosis treatment can be prescribed with either Independent Doses (ID) or Combined Fixed Doses (CFD), differentiated by the number of tablets. Assessing adherence to treatment is essential to improve its effectiveness. This study aimed to determine adherence to anti-tuberculosis treatment among patients receiving ID and FDC. A cross-sectional basic-descriptive study was carried out in the Trujillo Health Network with 114 patients diagnosed with tuberculosis, of whom 44.7% receive DFC and 55.3% DI. A validated 12-question questionnaire was applied to each patient attending the health centre. The results showed 90.2% adherence in the DFC group and 87.3% in the DI group, with no statistically significant differences between the two groups (p=0.6434). Despite the high adherence in both schemes, no significant difference was found. Although evidence suggests that CBD may facilitate adherence, further studies are needed to investigate efficacy and adherence in various settings.
Description
Keywords
Adherencia, Esquema de tratamiento, Dosis independientes, Dosis fijas combinadas